Unproven therapies for COVID

Lopinavir/Ritonavir (Kaletra®)
Recommendation: Recommend against the routine use of lopinavir/ritonavir outside a randomized- controlled trial.

Remdesivir
Recommendation: Recommend against the routine use of Remdesivir outside a randomized-controlled trial.

Chloroquine/Hydroxychloroquine
Recommendation: We recommend against the use of chloroquine and hydroxychloroquine for treatment or prophylaxis outside of a clinical trial

Oseltamivir Recommendation: Recommend against use of oseltamivir unless suspected or confirmed influenza infection.

Ribavirin and interferon
Recommendation: Strongly recommend against use of ribavirin and/or interferon for risk of harm.

Tocilizumab
Recommendation:Recommend against the routine use of Tocilizumab outside a randomized-controlled trial.

Steroids
Recommendation: Recommend against the use of steroids. However, steroids may be used if anothercompelling indication is present (e.g. asthma exacerbation, refractory septic shock).

Antibiotic Therapies Recommendation: If bacterial infection is suspected antibiotics should be initiated based on institutional antibiograms and sensitivities.

NSAIDs
Recommendation: Recommend acetaminophen use preferentially for symptomatic management of COVID-19 but do not recommend against the use of NSAIDs such as ibuprofen.

ACE inhibitors and ARBs
Recommendation: Recommend that patients on ACE inhibitors and ARBs continue these agents as indicated and not cease therapy solely on the basis of COVID-19.

Other investigational therapies
Recommendation: Recommend against any other investigational agent, including ASC09, azvudine, baloxavir marboxil/favipiravir, camostat mesylate, darunavir/cobicistat, camrelizumab, thymosin, natural health products, and traditional Chinese medicines due to lack of data, lack of availability, or both.

Reference:

http://www.bccdc.ca/Health-Professionals-Site/Dcouments/Guidelines